Clinical Trial Update: Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating maintenance therapy with a third-generation EGFR-TKI plus Anlotinib for non-small cell lung cancer with small cell transformation …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• Elunate (fruquintinib)
• TAGRISSO (osimertinib)

Snippet

Sponsor: Hunan Province Tumor Hospital | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: NOT_YET_RECRUITING